Targets › BTK
30 programs from 26 companies in 402 trials: 249 Phase 2, 75 Phase 3, 71 Phase 1, 7 Phase 4; Oncology, Neurology, Other; next expected readout Nov 2026.
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. (UniProt, Q06187)
Open in Phaseline: the race on BTK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Acalabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 4 | Chronic Lymphocytic Leukaemia; Untreated Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma; Mantle-cell Lymphoma … | Jan 2027 |
| Eli Lilly | Pirtobrutinib (LY3527727) Tyrosine-protein kinase BTK inhibitor | BTK | Phase 4 | Chronic Lymphocytic Leukemia; Lymphoma, Non-Hodgkin; Immune Thrombocytopenia (ITP) | Feb 2028 |
| Sanofi | rilzabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Immune Thrombocytopenia; Sickle Cell Disease; Autoimmune Haemolytic Anaemia; Immunoglobulin G4 Related Disease … | Nov 2026 |
| BeOne Medicines | Zanubrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | B-cell Malignancies; Relapsed/Refractory Follicular Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Non-Hodgkin Lymphoma … | Nov 2026 |
| Dizal Pharmaceuticals | DZD8586 (Birelentinib) Birelentinib; BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Immune Thrombocytopenia (ITP); Healthy; Diffuse Large B-Cell Lymphoma | Nov 2026 |
| BeOne Medicines | Tacabrutideg (BGB-16673) BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; CLL; Chronic Spontaneous Urticaria; B-cell Malignancy | Nov 2026 |
| Acerta Pharma | Acalabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; Lymphoma, Mantle Cell; Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma (MCL) … | Dec 2026 |
| Johnson & Johnson (Janssen) | Ibrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Anemia; Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type … | Dec 2026 |
| Nurix Therapeutics | NX-5948 Non-covalent BTK inhibitor | BTK | Phase 3 | B-cell Lymphoma; Chronic Lymphocytic Leukemia (CLL) | Jan 2027 |
| Merck & Co. (MSD) | Nemtabrutinib (MK-1026) Bruton's tyrosine kinase inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Hematologic Malignancies; Severe Renal Impairment … | Feb 2027 |
| Novartis | remibrutinib (LOU064) Bruton's tyrosine kinase (BTK) inhibitor | BTK | Phase 3 | Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa; Chronic Spontaneous Urticaria; Generalized Myasthenia Gravis … | Feb 2027 |
| Guangzhou Lupeng Pharmaceutical Company | Rocbrutinib (LP-168) BTK inhibitor | BTK | Phase 3 | Mantle Cell Lymphoma; Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma (DLBCL); Relapsing-remitting Multiple Sclerosis (RRMS) … | Mar 2027 |
| Ono Pharmaceutical | Tirabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Pemphigus; Relapsed/Refractory Primary Central Nervous System Lymphoma; Refractory Primary Central Nervous System Lymphoma; Primary Central Nervous System Lymphoma | Mar 2027 |
| Eli Lilly | Pirtobrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; Lymphoma, Mantle-Cell; Richter Syndrome; Mantle Cell Lymphoma … | May 2027 |
| Roche | Fenebrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Relapsing Multiple Sclerosis; Multiple Sclerosis, Primary Progressive | Jun 2027 |
| Beijing InnoCare Pharma Tech | Orelabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Relapsed/Refractory Marginal Zone Lymphoma; Hematologic Malignancies; Part 1:r/r B-cell Malignancies; OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma … | Aug 2028 |
| Sanofi | Tolebrutinib (SAR442168) Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Relapsing Multiple Sclerosis | Apr 2029 |
| Zenas BioPharma (USA) | Orelabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Secondary Progressive Multiple Sclerosis; Multiple Sclerosis (MS) Primary Progressive | Jun 2030 |
| Zhejiang Cancer Hospital | Zebutinib Bruton's tyrosine kinase (BTK) inhibitor | BTK | Phase 2 | Rituximab, Lenalidomide, Zebutinib ,Mantle Cell Lymphoma | Dec 2026 |
| NOBO Medicine | Poseltinib (NB02) Tyrosine-protein kinase BTK inhibitor | BTK | Phase 2 | Primary CNS Lymphoma (PCNSL); Non Hodgkin Lymphoma (NHL) | Dec 2026 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | QL1706 (eparbrutinib) Bruton's tyrosine kinase (BTK) inhibitor | BTK | Phase 2 | Neoadjuvant Immunotherapy | Mar 2027 |
| Bin Gu | Gecacitinib Bruton's tyrosine kinase (BTK) inhibitor | BTK | Phase 2 | aGVHD | Oct 2027 |
| The First Affiliated Hospital with Nanjing Medical University | Sonrotoclax BTK inhibitor | BTK | Phase 2 | CLL (Chronic Lymphocytic Leukemia) | Dec 2027 |
| Zhejiang Cancer Hospital | Thiotepa BTK inhibitor | BTK | Phase 2 | Pirtobrutinib | Aug 2028 |
| Shenzhen University General Hospital | Bugitinib Bruton's tyrosine kinase (BTK) inhibitor | BTK | Phase 2 | Acute Myeloid Leukemia | Jun 2029 |
| M.D. Anderson Cancer Center | BGB-16673 Bruton tyrosine kinase (BTK) degrader (PROTAC) | BTK | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | Jul 2031 |
| Carna Biosciences | AS-1763 (docirbrutinib) BTK inhibitor | BTK | Phase 1 | B-cell Malignancy | Sep 2027 |
| TransThera Sciences (Nanjing) | TT-01488 non-covalent reversible BTK inhibitor | BTK | Phase 1 | B-Cell Malignancies | Oct 2028 |
| Medolution | Keynatinib BTK inhibitor | BTK | Phase 1 | Lymphoma, B-Cell | Oct 2032 |
| Mingzhi Zhang | Obutinib Bruton's tyrosine kinase (BTK) inhibitor | BTK | Phase 1 | Newly Diagnosed Diffuse Large B-cell Lymphoma | – |
Chronic Lymphocytic Leukemia (67) Mantle Cell Lymphoma (32) Mantle Cell Lymphoma (MCL) (12) Diffuse Large B-Cell Lymphoma (9) Marginal Zone Lymphoma (9) Waldenstrom Macroglobulinemia (9) Chronic Lymphocytic Leukemia (CLL) (8) Primary Central Nervous System Lymphoma (8) Relapsing Multiple Sclerosis (8) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (7) Follicular Lymphoma (7) Marginal Zone Lymphoma(MZL) (6)
small molecule (22), mixed (6), antibody (2)
Sanofi (2) BeOne Medicines (2) Eli Lilly (2) Zhejiang Cancer Hospital (2) AstraZeneca (1) Guangzhou Lupeng Pharmaceutical Company (1) Zenas BioPharma (USA) (1) Carna Biosciences (1) Mingzhi Zhang (1) Merck & Co. (MSD) (1) Acerta Pharma (1) Beijing InnoCare Pharma Tech (1) Dizal Pharmaceuticals (1) Ono Pharmaceutical (1) Roche (1) Medolution (1) Nurix Therapeutics (1) Johnson & Johnson (Janssen) (1) Bin Gu (1) M.D. Anderson Cancer Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.